ClinicalTrials.gg
RecruitingNCT06592638Updated Aug 6, 2025

A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

A Phase 1 interventional study of ZG006 in Small Cell Lung Cancer, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 629 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Planned enrollment
367th of 550
30 · median 55
Started
2025
with 39 others
Phase 1
182 of 629
24 open now
Primary completion
2026-12
later than 43 of 181 live
Registered
556th of 629
by date

Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 367th largest by planned enrollment of the 550 interventional ones that give a count, is one of 40 that started in 2025, is one of 182 in phase 1, reaches primary completion later than 43 of the 181 other live ones, and was the 556th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

111 of the 629 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 629 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment. During the dose escalation stage, a standard "3+3" design will be used to assess the MTD/ recommended dose for the subsequent studies.

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Small cell lung cancer (SCLC), who failed or intolerant to available standard treatments;
  • Tissue sample positive for DLL3 expression;
  • ≥ 3 months;
  • (ECOG) Performance Status of 0 or 1;
  • Female and Male patients must agree to use a reliable form of during the study treatment period and for at least 6 months after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

  • Patients having received any of the following treatments:

    • Chemotherapy, biotherapy, endocrine therapy (except for hormone replacement), and biological targeted medicines ≤ 4 weeks before the study entry. Local palliative radiotherapy and a small molecule targeted therapy ≤ 2 weeks (or 5 half-lives, whichever is longer) before the study entry;
    • Systemic medications, such as (doses \> 10 mg/day prednisone or equivalent dose) within 14 days prior to the study entry;
    • Use of any vaccines against viral infections (COVID-19, influenza, varicella, etc.) within 4 weeks of study entry;
  • Patients received any blood transfusion, EPO, G-CSF, albumin infusion and renal replacement therapy within 14 days prior to study entry;
  • A history of severe, life-threatening immune-mediated adverse events or infusion-related reactions during previous anti-tumor immunotherapy, including events that led to permanent discontinuation of treatment;
  • Active infection (such as acute bacterial infection, tuberculosis, active /C, active syphilis, or active infection);
  • Known allergy to other mAbs or any antibody ; the history of a severe allergic reaction, anaphylactoid or other reactions to humanized antibodies or fusion proteins;
  • A female who is pregnant or nursing;
  • Patients were deemed unsuitable for participating in the study by the investigator for any reason.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Drug: ZG006

Interventions

  • DrugZG006

    ZG006 will be administered as an intravenous (IV) infusion.

06

What researchers measure

Primary outcomes

  1. The incidence of dose-limiting toxicity (DLT)

    An event is considered to be a DLT if the event occurs within the first 28 days of treatment and meets the dose-limiting toxicity criteria

    Time frame: Up to 28 days

  2. Maximum Tolerated Dose (MTD) of ZG006

    Time frame: Approximately 2 years

  3. Determine the Recommended Phase 2 Dose (RP2D)

    Time frame: Approximately 2 years

  4. Number of participants with adverse events (AEs)

    The types and frequencies of adverse events (AEs) evaluated according to the National Cancer Institute Common Terminology Criteria for adverse events (NCI-CTCAE) version 5.0

    Time frame: Approximately 2 years

  5. Number of participants with serious adverse events (SAEs)

    Time frame: Approximately 2 years

  6. Incidence of abnormal laboratory results

    Time frame: Approximately 2 years

Secondary outcomes

  1. Objective response rate (ORR)

    ORR is defined as the percentage of participants achieving a confirmed complete response (CR) or partial response (PR) based on RECIST 1.1 criteria.

    Time frame: Approximately 2 years

  2. Duration of response (DOR)

    DOR is defined as the time from first evidence of response (CR or PR per RECIST 1.1) to earlier date of disease progression or death due to any cause

    Time frame: Approximately 2 years

  3. Disease control rate (DCR)

    Time frame: Approximately 2 years

  4. Maximum plasma concentration (Cmax) of ZG006

    Time frame: Approximately 2 years

  5. Time to peak concentration (Tmax)

    Time frame: Approximately 2 years

  6. AUC from time zero to the last quantifiable concentration after dosing (AUC[0-t]) of ZG006

    Time frame: Approximately 2 years

  7. Terminal phase half-life (t1/2) of ZG006

    Time frame: Approximately 2 years

  8. Detection of anti-drug antibodies (ADA)

    Time frame: Approximately 2 years

07

Study locations

3 of 6 sites recruiting
  • Zelgen Site 105
    Orange, California 92868, United States
    Not yet recruiting
  • Zelgen Site 102
    Plantation, Florida 33322, United States
    Recruiting
  • Zelgen Site 103
    Lexington, Kentucky 40536, United States
    Recruiting
  • Zelgen Site 101
    Canton, Ohio 44718, United States
    Recruiting
  • Zelgen Site 104
    Cleveland, Ohio 44106, United States
    Not yet recruiting
  • Zelgen Site 106
    Houston, Texas 77030, United States
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's planned 21 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2024
First posted
Sep 19, 2024
StartActual
Mar 31, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06592638
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Mar 31, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Aug 6, 2025

Study contacts

Zelgen
Contact
liusc@zelgen.com
+86-02158942758

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alveltamig

Start the discussion